Issued Patents All Time
Showing 51–75 of 156 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 9540435 | Stably tethered structures of defined compositions with multiple functions or binding specificities | David M. Goldenberg, William J. McBride, Edmund A. Rossi | 2017-01-10 |
| 9540618 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses | David M. Goldenberg, William J. McBride, Edmund A. Rossi | 2017-01-10 |
| 9518115 | Humanized anti-CD22 antibody | David M. Goldenberg | 2016-12-13 |
| 9498542 | Tetrameric cytokines with improved biological activity | David M. Goldenberg, Edmund A. Rossi | 2016-11-22 |
| 9492561 | Dock-and-Lock (DNL) Complexes for delivery of interference RNA | David M. Goldenberg | 2016-11-15 |
| 9481878 | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity | David M. Goldenberg, Edmund A. Rossi | 2016-11-01 |
| 9475883 | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis | David M. Goldenberg, Hans J. Hansen, Edmund A. Rossi | 2016-10-25 |
| 9457072 | Dock-and-lock (DNL) vaccines for cancer therapy | David M. Goldenberg | 2016-10-04 |
| 9457100 | PEGylation by the dock and lock (DNL) technique | David M. Goldenberg, William J. McBride, Edmund A. Rossi | 2016-10-04 |
| 9452228 | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) | Donglin Liu, David M. Goldenberg | 2016-09-27 |
| 9446123 | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy | Edmund A. Rossi, David M. Goldenberg | 2016-09-20 |
| 9441043 | Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R) | Michele J. Losman, David M. Goldenberg | 2016-09-13 |
| 9416197 | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease | David M. Goldenberg, Rongxiu Li | 2016-08-16 |
| 9382329 | Disease therapy by inducing immune response to Trop-2 expressing cells | David M. Goldenberg, Edmund A. Rossi, Diane Rossi | 2016-07-05 |
| 9371393 | Class I anti-CEA antibodies and uses thereof | Hans J. Hansen, David M. Goldenberg | 2016-06-21 |
| 9359443 | Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases | David M. Goldenberg, Edmund A. Rossi | 2016-06-07 |
| 9352036 | Delivery system for cytotoxic drugs by bispecific antibody pretargeting | William J. McBride, Christopher A. D'Souza, David M. Goldenberg | 2016-05-31 |
| 9315567 | T-cell redirecting bispecific antibodies for treatment of disease | David M. Goldenberg, Edmund A. Rossi, Diane Rossi | 2016-04-19 |
| 9278129 | Methods of treating rapidly progressive glomerulonephritis using chimeric and humanized anti-histone H4 antibodies | Hans J. Hansen, David M. Goldenberg | 2016-03-08 |
| 9272029 | Interferon lambada-antibody complexes | David M. Goldenberg, Donglin Liu | 2016-03-01 |
| 9248184 | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy | David M. Goldenberg | 2016-02-02 |
| 9238084 | Anti-mucin antibodies for early detection and treatment of pancreatic cancer | Donglin Liu, David V. Gold, Serengulam V. Govindan, David M. Goldenberg | 2016-01-19 |
| 9192664 | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis | David M. Goldenberg, Hans J. Hansen, Edmund A. Rossi | 2015-11-24 |
| 9187561 | Humanized anti-HLA-DR antibodies | David M. Goldenberg, Hans J. Hansen | 2015-11-17 |
| 9184781 | Humanized antibodies and methods of humanizing antibodies | Hans J. Hansen, Edmund A. Rossi, David M. Goldenberg | 2015-11-10 |